ABSTRACT
The three main theories explaining major mental illness, namely mood disorders, psychoses and dementias, have been partially discredited. Alongside this, there are emerging links between perturbations of the immune system and the onset and phenotypic features of these disorders. This article outlines the alternative pathophysiology and suggests potential treatments which could improve disease burden and avoid the need for psychotropic medication, with their associated side effects and relapse following withdrawal.
Subject(s)
Mental Disorders , Mental Disorders/immunology , Mental Disorders/therapy , Humans , Immune SystemABSTRACT
1. Drinks sweetened with both sugar and artificial additives lead to dopamine release at the nucleus accumbens (NAc) in rat models; the basis of experiences of pleasure in humans, resulting in impulsive binging behaviour at times. 2. Evidence from rat models show cross sensitisation between sweetened drinks, alcohol, opiates and stimulants. Therefore, it could be hypothesised that sweetened drinks could be a gateway to multiple substance abuse among humans via 'alcopops'. 3. Identification of an allelic variant of the cyclic adenosine monophosphate responsive element modulator gene (CREM), linking impulsivity and multiple substance abuse, opens up prospects of mass screening to advice on harm reduction. 4. Furthermore, therapies involving cannabinoid receptor antagonists and transcranial brain stimulation are being currently investigated; of benefit to limit binge use of sweetened drinks.
Subject(s)
Alcoholism/etiology , Amphetamine-Related Disorders/etiology , Nucleus Accumbens/drug effects , Opioid-Related Disorders/etiology , Sugar-Sweetened Beverages/adverse effects , Alcohol Drinking , Alcoholic Beverages/adverse effects , Alleles , Analgesics, Opioid/adverse effects , Animals , Central Nervous System Stimulants/adverse effects , Cyclic AMP Response Element Modulator/genetics , Endocannabinoids/metabolism , Genetic Variation , Humans , Nucleus Accumbens/physiopathology , Rats , RiskABSTRACT
This article reviews currently available appropriate technologies which have been used in mental health, in order to reduce confusion and delay. Confusion (for example when and where to refer) can lead to error and waste. Similarly delay impacts quality and accessibility of the whole range of mental health services. As most secondary care mental health services use electronic patient records, it is arguably easier to apply technology in this speciality. However, consideration needs to be given to confidentiality and data security. Doctors of all specialities will be exposed to 'new' technologies over the next decade, and need to be aware of the direction of travel and its implications.
Subject(s)
Mental Disorders/therapy , Mental Health Services/organization & administration , Referral and Consultation/organization & administration , Technology/organization & administration , Computer Security/standards , Confidentiality/standards , Electronic Health Records/organization & administration , Humans , Mental Disorders/diagnosis , Mental Health Services/standards , Mobile Applications , Quality of Health Care/organization & administration , Smartphone , State Medicine , Technology/methods , Technology/standards , Telemedicine/methods , Time-to-Treatment , United KingdomABSTRACT
This article discusses options for closing the mortality gap between the general population and people with major psychiatric conditions such as psychosis, autism, learning disability and dementia. Most of the mortality (85%) involves physical disease, with most deaths occurring in general hospitals or care homes, so is relevant to all doctors. The main focus of psychiatric treatments has been to reduce suicide, although there is no evidence that they achieve this. This article calls for psychiatrists to collaborate with medical colleagues to help reduce excess deaths from physical causes. The practicalities of combined physical and mental health monitoring and prescribing clinics are discussed, based on experience in Whitby. Potential national solutions are summarized including options for smoking cessation, sugar restriction, nutritional supplementation and flu vaccination.
Subject(s)
Mental Disorders/mortality , Neurodevelopmental Disorders/mortality , Patient Care Management , Physicians , Preventive Health Services , Psychiatry , Humans , Interdisciplinary Communication , Mental Disorders/classification , Mortality , Neurodevelopmental Disorders/classification , Patient Care Management/methods , Patient Care Management/organization & administration , Patient Care Management/standards , Preventive Health Services/methods , Preventive Health Services/organization & administration , Quality ImprovementABSTRACT
All effective anti psychotic drugs block glucose transporter proteins (GLUTs), peripherally and in the brain. These drugs are implicated in hyperglycaemia as demonstrated in mouse and human studies. Clozapine is the strongest blocker, with Haloperidol the weakest. The GLUT hypothesis suggests that schizophrenia is partly due to poor functioning of brain glucose transporters (GLUT 1 and 3). Neuronal glucose malnutrition could result in excessive neuronal pruning (so called Crow's Type 2 with a predominance of negative symptoms) or result in recurrent/ineffective pruning (Type 1 with positive symptoms). GLUT blockade by anti psychotic agents could assist Type 1 patients to complete the pruning process by deactivating already damaged neurones and circuits, but will make Type 2 patients more cognitively impaired. Future treatment options are discussed in line with the above formulation.
